| Oncology Hero |
Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe.
| Sponsor: Novartis Pharma AG | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Institut Curie | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Medica Scientia Innovation Research S.L. | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: AstraZeneca AB | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Heinrich-Heine-Universitaet Duesseldorf | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: AbbVie Deutschland GmbH & Co. KG | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Summit Therapeutics Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Akershus University Hospital | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Unicancer | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Centro Di Riferimento Oncologico Di Aviano | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Bristol-Myers Squibb Services Unlimited Company | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Centro Di Riferimento Oncologico Di Aviano | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Universita' Vita-salute S. Raffaele | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: JJP BIOLOGICS Sp. z o.o. | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Evexta Bio | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Systimmune Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator Interest| Sponsor: Radboud universitair medisch centrum Stichting | Phase: |
Not accepting new sites
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Sharing the latest updates in oncology
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1) Sponsor: Eli Lilly & Co. Phase: Interested in offering this trial to suitable patients? Register Investigator Interest A multicentre open-label phase I/Ib trial of melanoma-specific peptide vaccination (UniCanVax) combined...
Oncology Hero 9 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer Sponsor: Celcuity Inc. Phase: 3 Interested in offering...
Oncology Hero 12 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. Sponsor: European Organisation For Research And Treatment Of Cancer Phase:...